Role of 18F-FDG PET for evaluating Malignant Pleural Mesothelioma

Cristina Nanni, Paolo Castellucci, Mohsen Farsad, Carmine Pinto, Andrea Moretti, Cinzia Pettinato, Mario Marengo, Stefano Boschi, Roberto Franchi, Andrea Martoni, Nino Monetti, Stefano Fanti

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

Malignant Pleural Mesothelioma (MPM) is a relatively rare neoplasia characterized by a poor prognosis. Recent studies show that new therapeutic approaches can lead to an improvement in life quality and to a prolonged survival; therefore, proper evaluation of MPM before, as well as after, therapy, is needed. The aim of this study was to evaluate the impact of 18F-FDG photon emission tomography (PET) scan compared to computed tomography (CT) findings in patients affected by MPM, whether untreated or already treated. We studied 15 consecutive patients (13 male and 2 female) with a histological diagnosis of MPM, with a mean age of 69.9 years (range: 38-78 years old) and a recent total-body CT scan. Five (5) patients were studied for staging, while 10 patients were studied after therapy. An FDG PET scan was carried out 60 minutes after an intravenous (i.v.) injection of 370 MBq of 18F-FDG. For each patient, we compared the PET stage to the CT stage, and evaluated the role of PET in choosing a therapeutic approach. In 9 of 15 (60%) patients, there was no difference between the PET and the CT stage. In 2 of 15 (13%) patients, PET upstaged the disease, while in 4 of 15 (27%) patients PET downstaged MPM. According to these results, patient management was changed in 3 cases. Specifically, 1 patient was excluded from surgery, and 2 patients had different chemotherapy. These data suggest that PET is useful in the evaluation of MPM, giving additional data that can clarify doubtful CT findings, especially regarding lymph node involvement and distant lesions. In conclusion, FDG PET was found to play a worthwhile role in patient management.

Original languageEnglish
Pages (from-to)149-154
Number of pages6
JournalCancer Biotherapy and Radiopharmaceuticals
Volume19
Issue number2
DOIs
Publication statusPublished - 2004

Fingerprint

Fluorodeoxyglucose F18
Photons
Tomography
Malignant Mesothelioma
Emission-Computed Tomography
Therapeutics
Intravenous Injections
Lymph Nodes
Quality of Life

Keywords

  • F-FDG PET
  • Computed tomography
  • Malignant pleural mesothelioma

ASJC Scopus subject areas

  • Cancer Research
  • Pharmacology
  • Oncology

Cite this

Nanni, C., Castellucci, P., Farsad, M., Pinto, C., Moretti, A., Pettinato, C., ... Fanti, S. (2004). Role of 18F-FDG PET for evaluating Malignant Pleural Mesothelioma. Cancer Biotherapy and Radiopharmaceuticals, 19(2), 149-154. https://doi.org/10.1089/108497804323071913

Role of 18F-FDG PET for evaluating Malignant Pleural Mesothelioma. / Nanni, Cristina; Castellucci, Paolo; Farsad, Mohsen; Pinto, Carmine; Moretti, Andrea; Pettinato, Cinzia; Marengo, Mario; Boschi, Stefano; Franchi, Roberto; Martoni, Andrea; Monetti, Nino; Fanti, Stefano.

In: Cancer Biotherapy and Radiopharmaceuticals, Vol. 19, No. 2, 2004, p. 149-154.

Research output: Contribution to journalArticle

Nanni, C, Castellucci, P, Farsad, M, Pinto, C, Moretti, A, Pettinato, C, Marengo, M, Boschi, S, Franchi, R, Martoni, A, Monetti, N & Fanti, S 2004, 'Role of 18F-FDG PET for evaluating Malignant Pleural Mesothelioma', Cancer Biotherapy and Radiopharmaceuticals, vol. 19, no. 2, pp. 149-154. https://doi.org/10.1089/108497804323071913
Nanni, Cristina ; Castellucci, Paolo ; Farsad, Mohsen ; Pinto, Carmine ; Moretti, Andrea ; Pettinato, Cinzia ; Marengo, Mario ; Boschi, Stefano ; Franchi, Roberto ; Martoni, Andrea ; Monetti, Nino ; Fanti, Stefano. / Role of 18F-FDG PET for evaluating Malignant Pleural Mesothelioma. In: Cancer Biotherapy and Radiopharmaceuticals. 2004 ; Vol. 19, No. 2. pp. 149-154.
@article{79ece195dfc840d3b39a6c6c7781173a,
title = "Role of 18F-FDG PET for evaluating Malignant Pleural Mesothelioma",
abstract = "Malignant Pleural Mesothelioma (MPM) is a relatively rare neoplasia characterized by a poor prognosis. Recent studies show that new therapeutic approaches can lead to an improvement in life quality and to a prolonged survival; therefore, proper evaluation of MPM before, as well as after, therapy, is needed. The aim of this study was to evaluate the impact of 18F-FDG photon emission tomography (PET) scan compared to computed tomography (CT) findings in patients affected by MPM, whether untreated or already treated. We studied 15 consecutive patients (13 male and 2 female) with a histological diagnosis of MPM, with a mean age of 69.9 years (range: 38-78 years old) and a recent total-body CT scan. Five (5) patients were studied for staging, while 10 patients were studied after therapy. An FDG PET scan was carried out 60 minutes after an intravenous (i.v.) injection of 370 MBq of 18F-FDG. For each patient, we compared the PET stage to the CT stage, and evaluated the role of PET in choosing a therapeutic approach. In 9 of 15 (60{\%}) patients, there was no difference between the PET and the CT stage. In 2 of 15 (13{\%}) patients, PET upstaged the disease, while in 4 of 15 (27{\%}) patients PET downstaged MPM. According to these results, patient management was changed in 3 cases. Specifically, 1 patient was excluded from surgery, and 2 patients had different chemotherapy. These data suggest that PET is useful in the evaluation of MPM, giving additional data that can clarify doubtful CT findings, especially regarding lymph node involvement and distant lesions. In conclusion, FDG PET was found to play a worthwhile role in patient management.",
keywords = "F-FDG PET, Computed tomography, Malignant pleural mesothelioma",
author = "Cristina Nanni and Paolo Castellucci and Mohsen Farsad and Carmine Pinto and Andrea Moretti and Cinzia Pettinato and Mario Marengo and Stefano Boschi and Roberto Franchi and Andrea Martoni and Nino Monetti and Stefano Fanti",
year = "2004",
doi = "10.1089/108497804323071913",
language = "English",
volume = "19",
pages = "149--154",
journal = "Cancer Biotherapy and Radiopharmaceuticals",
issn = "1084-9785",
publisher = "Mary Ann Liebert Inc.",
number = "2",

}

TY - JOUR

T1 - Role of 18F-FDG PET for evaluating Malignant Pleural Mesothelioma

AU - Nanni, Cristina

AU - Castellucci, Paolo

AU - Farsad, Mohsen

AU - Pinto, Carmine

AU - Moretti, Andrea

AU - Pettinato, Cinzia

AU - Marengo, Mario

AU - Boschi, Stefano

AU - Franchi, Roberto

AU - Martoni, Andrea

AU - Monetti, Nino

AU - Fanti, Stefano

PY - 2004

Y1 - 2004

N2 - Malignant Pleural Mesothelioma (MPM) is a relatively rare neoplasia characterized by a poor prognosis. Recent studies show that new therapeutic approaches can lead to an improvement in life quality and to a prolonged survival; therefore, proper evaluation of MPM before, as well as after, therapy, is needed. The aim of this study was to evaluate the impact of 18F-FDG photon emission tomography (PET) scan compared to computed tomography (CT) findings in patients affected by MPM, whether untreated or already treated. We studied 15 consecutive patients (13 male and 2 female) with a histological diagnosis of MPM, with a mean age of 69.9 years (range: 38-78 years old) and a recent total-body CT scan. Five (5) patients were studied for staging, while 10 patients were studied after therapy. An FDG PET scan was carried out 60 minutes after an intravenous (i.v.) injection of 370 MBq of 18F-FDG. For each patient, we compared the PET stage to the CT stage, and evaluated the role of PET in choosing a therapeutic approach. In 9 of 15 (60%) patients, there was no difference between the PET and the CT stage. In 2 of 15 (13%) patients, PET upstaged the disease, while in 4 of 15 (27%) patients PET downstaged MPM. According to these results, patient management was changed in 3 cases. Specifically, 1 patient was excluded from surgery, and 2 patients had different chemotherapy. These data suggest that PET is useful in the evaluation of MPM, giving additional data that can clarify doubtful CT findings, especially regarding lymph node involvement and distant lesions. In conclusion, FDG PET was found to play a worthwhile role in patient management.

AB - Malignant Pleural Mesothelioma (MPM) is a relatively rare neoplasia characterized by a poor prognosis. Recent studies show that new therapeutic approaches can lead to an improvement in life quality and to a prolonged survival; therefore, proper evaluation of MPM before, as well as after, therapy, is needed. The aim of this study was to evaluate the impact of 18F-FDG photon emission tomography (PET) scan compared to computed tomography (CT) findings in patients affected by MPM, whether untreated or already treated. We studied 15 consecutive patients (13 male and 2 female) with a histological diagnosis of MPM, with a mean age of 69.9 years (range: 38-78 years old) and a recent total-body CT scan. Five (5) patients were studied for staging, while 10 patients were studied after therapy. An FDG PET scan was carried out 60 minutes after an intravenous (i.v.) injection of 370 MBq of 18F-FDG. For each patient, we compared the PET stage to the CT stage, and evaluated the role of PET in choosing a therapeutic approach. In 9 of 15 (60%) patients, there was no difference between the PET and the CT stage. In 2 of 15 (13%) patients, PET upstaged the disease, while in 4 of 15 (27%) patients PET downstaged MPM. According to these results, patient management was changed in 3 cases. Specifically, 1 patient was excluded from surgery, and 2 patients had different chemotherapy. These data suggest that PET is useful in the evaluation of MPM, giving additional data that can clarify doubtful CT findings, especially regarding lymph node involvement and distant lesions. In conclusion, FDG PET was found to play a worthwhile role in patient management.

KW - F-FDG PET

KW - Computed tomography

KW - Malignant pleural mesothelioma

UR - http://www.scopus.com/inward/record.url?scp=2542505264&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=2542505264&partnerID=8YFLogxK

U2 - 10.1089/108497804323071913

DO - 10.1089/108497804323071913

M3 - Article

C2 - 15186594

AN - SCOPUS:2542505264

VL - 19

SP - 149

EP - 154

JO - Cancer Biotherapy and Radiopharmaceuticals

JF - Cancer Biotherapy and Radiopharmaceuticals

SN - 1084-9785

IS - 2

ER -